Bayshore Asset Management’s AbbVie ABBV Stock Holding History

Bayshore Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$298K	Buy	+1,186	New	+$255K	0.11%	45

Other funds holding ABBV

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Bayshore Asset Management's ABBV Position: Q2 2026 in Review

Bayshore Asset Management opened a new position in AbbVie (ABBV) in Q2 2026: 1,186 shares worth $298K. The stake represents 0.11% of the portfolio and ranks #45 among its holdings.

2,479 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Bayshore Asset Management held 1,186 shares of AbbVie worth $298K as of Q2 2026.
AbbVie was a new Bayshore Asset Management position in Q2 2026.
AbbVie made up 0.11% of Bayshore Asset Management's portfolio in Q2 2026, its #45 holding.
2,479 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Bayshore Asset Management's 13F filing for Q2 2026, filed 23 Jul 2026.